ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.519,38
-0,41%
S&P 500
5.614,56
-2,70%
US Dollar vs BRL
5,8568
0,04%
Bitcoin
79.439,74
1,23%
Brent Oil
69,115
0,11%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Tenaya Therapeutics Inc (TNYA)

  7. Tenaya Therapeutics Inc (TNYA) Notícias

TNYA

Tenaya Therapeutics (TNYA)

Tenaya Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TNYA
DataHoraFonteTítuloCódigoCompanhia
10/03/202522:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
10/03/202522:41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNYATenaya Therapeutics Inc
10/03/202517:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TNYATenaya Therapeutics Inc
10/03/202517:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
10/03/202517:05GlobeNewswire Inc.Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
04/03/202518:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TNYATenaya Therapeutics Inc
04/03/202501:19GlobeNewswire Inc.Tenaya Therapeutics Announces Pricing of Public OfferingNASDAQ:TNYATenaya Therapeutics Inc
03/03/202518:10GlobeNewswire Inc.Tenaya Therapeutics Announces Proposed Public OfferingNASDAQ:TNYATenaya Therapeutics Inc
03/03/202518:04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TNYATenaya Therapeutics Inc
03/03/202510:00GlobeNewswire Inc.Tenaya Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:TNYATenaya Therapeutics Inc
07/02/202522:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
07/02/202518:58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TNYATenaya Therapeutics Inc
05/02/202515:23Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:TNYATenaya Therapeutics Inc
03/02/202510:30GlobeNewswire Inc.Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative MedicineNASDAQ:TNYATenaya Therapeutics Inc
13/01/202511:16GlobeNewswire Inc.Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated MilestonesNASDAQ:TNYATenaya Therapeutics Inc
17/12/202409:00GlobeNewswire Inc.Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
16/12/202418:30GlobeNewswire Inc.Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024NASDAQ:TNYATenaya Therapeutics Inc
25/11/202410:30GlobeNewswire Inc.Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
19/11/202410:00GlobeNewswire Inc.Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:TNYATenaya Therapeutics Inc
06/11/202418:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNYATenaya Therapeutics Inc
06/11/202418:05GlobeNewswire Inc.Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
17/10/202417:30GlobeNewswire Inc.Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCMNASDAQ:TNYATenaya Therapeutics Inc
03/09/202409:30GlobeNewswire Inc.Tenaya Therapeutics to Participate in Upcoming Investment ConferencesNASDAQ:TNYATenaya Therapeutics Inc
08/08/202417:05GlobeNewswire Inc.Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
27/06/202418:00GlobeNewswire Inc.Tenaya Therapeutics Announces Research Leadership UpdatesNASDAQ:TNYATenaya Therapeutics Inc
18/06/202417:30GlobeNewswire Inc.Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA SummitNASDAQ:TNYATenaya Therapeutics Inc
14/05/202417:05GlobeNewswire Inc.Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
02/05/202418:00GlobeNewswire Inc.Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:TNYATenaya Therapeutics Inc
18/03/202417:05GlobeNewswire Inc.Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
18/03/202409:30GlobeNewswire Inc.Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications MedicineNASDAQ:TNYATenaya Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TNYA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
PDGR3
PDG REALT ON
BOV
TPIS3
TRIUNFO PART ON
BOV
TECN3
TECHNOS ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios